NCT00953914

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients With Autonomic Neuropathy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Hospital de Clinicas de Porto Alegre · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine if pyridostigmine bromide improves heart rate variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy.

Detailed description

The reduced heart rate variability is associated with increased risk of death in patients with diabetes mellitus. Cholinesterase inhibition with pyridostigmine bromide increases heart rate variability in normal individuals and congestive heart failure subjects but its effects on patients with diabetes mellitus is unknown. Based on those evidences, we will test if the short-term administration of pyridostigmine bromide increases heart rate variability in patients with diabetes mellitus.

Conditions

• Diabetes Complications

Interventions

Type	Name	Description
DRUG	Pyridostigmine	Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
DRUG	Placebo	If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days

Timeline

• Start date: 2005-03-01
• Primary completion: 2009-07-01
• Completion: 2010-05-01
• First posted: 2009-08-06
• Last updated: 2011-07-07

Locations

1 site across 1 country: Brazil